Awardee OrganizationWEILL MEDICAL COLL OF CORNELL UNIV
Description
Abstract Text
ABSTRACT – Nonhuman Primate (NHP) Core (Core 1, Leader: Dr. GuidoSilvestri, Yerkes National
Primate Research Center, Emory University)
The most appropriate animal model to define the origin, kinetics, and impact of humoral and cellular immune-
based strategies on viral rebound in infants following postnatal HIV-1 infection and treatment is simian
immunodeficiency virus (SIV)/simian-human immunodeficiency virus (SHIV) infection of rhesus macaques.
Indeed, this model is particularly well-suited for our proposed studies because pediatric models of postnatal
transmission have been developed and used to define the pathogenesis of infant HIV-1 infection and
prevention strategies. However, NHP studies require extensive infrastructure and unique expertise. Thus, we
the Program's Nonhuman Primate (NHP) Core (Core 1) will coordinate and implement all the NHP experiments
proposed by the Program's two Projects: Project 1: “Origin and predictors of viral rebound in infants”, (PI: Dr.
Ann Chahroudi, Emory University), and Project 2: “Impact of immune-based intervention on viral rebound in
orally SHIV-infected infant monkeys” (PI: Dr. Genevieve Fouda, Duke University). The Core will support the
Program through the following Specific Aims: Aim 1 - Organize, coordinate, and conduct studies of infant SHIV
reservoir and rebound; Aim 2 - Administer and monitor antiretroviral treatment (ART) in orally SHIV-infected
infant monkeys; and Aim 3 - Perform pharmacokinetic analysis of polyclonal antibody infusions in infant
macaques to determine the dose and administration interval for treatment of infant SHIV infection. Led by Dr.
GuidoSilvestri, the NHP Core will ensure the following that are essential to the successful completion of these
projects: 1) adherence to regulatory procedures relevant to research with NHPs; 2) coordination and
implementation of all animal-related procedures, including housing, immunizations of infants, nursery-rearing of
infants, antiretroviral treatments, and sample collections for weekly viral load measurement and monthly blood
counts; 3) proper storage and/or shipment of samples to the Projects and Cores; and 4) maintenance of a
database of clinical health parameters. Dr. Silvestri will ensure all NHP supported research efforts are tightly
integrated and that evolving needs of the research projects will be met. As an integral component of this
Program, the NHP Core will provide critical support to achieve the shared goals of understanding the source,
kinetics, and impact of immune interventions on HIV-1 rebound in postnatally infected infants.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
060217502
UEI
YNT8TCJH8FQ8
Project Start Date
24-July-2017
Project End Date
30-June-2022
Budget Start Date
01-March-2021
Budget End Date
30-June-2021
Project Funding Information for 2020
Total Funding
$400,441
Direct Costs
$383,066
Indirect Costs
$17,375
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$400,441
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7P01AI131276-05 7150
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7P01AI131276-05 7150
Patents
No Patents information available for 7P01AI131276-05 7150
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7P01AI131276-05 7150
Clinical Studies
No Clinical Studies information available for 7P01AI131276-05 7150
News and More
Related News Releases
No news release information available for 7P01AI131276-05 7150
History
No Historical information available for 7P01AI131276-05 7150
Similar Projects
No Similar Projects information available for 7P01AI131276-05 7150